Pfizer's (NYSE: PFE ) stock is currently weighed down by a significant credibility discount. Much of this stems from the near-total loss of its $5.4 billion acquisition of Global Blood Therapeutics in 2022, a failure thatWilliam has been an avid student of the stock market for over a decade. Being an avid student of political economics his entire professional life gives him a unique insight into the macroeconomy and how it impacts assets. Having learned the value of a comprehensive and fundamental approach, ...